American Academy of Neurology 2020

Onset of pain relief occurs one hour after acute treatment with ubrogepant, according to pooled data from the ACHIEVE-I and ACHIEVE-II trials in patients with migraine. Results showed that statistically significant onset of pain relief was achieved with ubrogepant 50 mg compared to placebo at one hour. Significant differences occurred for most bothersome symptoms (MBS) …

A retrospective analysis of adverse event (AE) reports to the Food and Drug Administration (FDA) during the first six months after US approval of erenumab, fremanezumab and galcanezumab has shown that migraine, headache or drug ineffective AEs were common for all three drugs. Constipation was the second most common AE with erenumab but was not …

Rimegepant 75 mg, when used as an oral acute treatment in patients receiving preventive anti-CGRP monoclonal antibodies, demonstrated favourable tolerability and no safety issues in a small sample of adults with migraine. This is the conclusion of the authors of a sub group analysis of data from a multicentre, long term, open label rimegepant safety …

At least 70% of patients with acute medication overuse (AMO) went into remission after 12 months of erenumab treatment, according to a sub-group analysis of data from an open label extension study in chronic migraine (NCT02174861). Of the 609 patients in the study, 252 (41%) had AMO at baseline of the original double blind study …

Addition of galcanezumab to botulinumtoxin A treatment in patients with chronic migraine has been associated with a reduction in monthly migraine headache days (MHDs). In a report of 10 patients with chronic migraine, mean MHDs in the first month after treatment with galcanezumab was 15.9 ± 1.0, compared to 16.4 ± 1.2 after botulinum treatment …

Switching patients who experience ‘wear off’ with erenumab 140 mg to erenumab 70 mg every 14 days may reduce monthly headache frequency and severity, while maintaining a mild side effect profile, according to US clinicians. Through a retrospective chart review, they identified 17 patients started on erenumab 140mg monthly who had a >50% reduction in …

Over two-thirds of patients with episodic or chronic migraine prefer quarterly fremanezumab dosing over monthly dosing. Results of a retrospective survey of 253 patients carried out 1-24 months after completing a fremanezumab 52-week extension study showed that 69% of respondents preferred quarterly dosing. A similar proportion expressed a preference for quarterly dosing whether they had …

Over six months, patients with episodic migraine treated with eptinezumab can expect to gain back approximately one month of migraine-free days and those with chronic migraine can expect approximately two months.1 These findings come from post hoc analyses of PROMISE-1 and PROMISE-2 data which calculated the expected number of migraine days over a year (baseline …

Patients with high migraine polygenic risk scores (mPRS) appear to have an earlier onset of migraine, are more likely to fail on preventive therapies and require greater use of acute migraine-specific medication (AMSM). These are some of the findings from a study in which blood samples from 1585 participants in four erenumab trials were genotyped …

Migraine admission rates to US hospitals doubled between 2002 and 2015, with an accompanying greater annual increase in cost than for all-cause admissions. Using the Healthcare Cost and Utilization Project Nationwide Inpatient Sample database, researchers found that 1,110,649 (1.12%) of 99,155,348 patients admitted between 2002 and 2015 had a primary diagnosis of migraine. Migraine admission …